| 01/25 | Zymeworks Announces Participation in Upcoming Investor Conferences | BU |
| 01/20 | Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas.. | AQ |
| 01/20 | SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perfor.. | MT |
| 01/19 | Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophag.. | MT |
| 01/19 | Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Pha.. | CI |
| 01/12 | Transcript : Zymeworks Inc. Presents at 41st Annual J.P. Morgan Healthcare Co.. | CI |
| 01/04 | Zymeworks Updates on Cash Resources; Chief Medical Officer to Depart Amid Internal Reor.. | MT |
| 01/04 | Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer | CI |
| 01/04 | Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 | BU |
| 01/04 | HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Ratin.. | MT |
| 2022 | Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part.. | AQ |
| 2022 | Barclays Adjusts Zymeworks Price Target to $9 From $7, Maintains Equal Weight Rating | MT |
| 2022 | Jazz Pharmaceuticals Exercises Option to Continue Exclusive Rights to Zymeworks' Zanida.. | MT |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conference | BU |
| 2022 | Jazz Pharmaceuticals plc and Zymeworks Announce Jazz Has Confirmed Opt-In and Advances .. | CI |
| 2022 | North American Morning Briefing: Futures Rise -2- | DJ |
| 2022 | Zymeworks Announces Positive Topline Data in The Pivotal HERIZON-BTC-01 Trial Of Zanida.. | AQ |
| 2022 | Jefferies Upgrades Zymeworks to Buy From Hold, Adjusts Price Target to $11 From $7.70 | MT |
| 2022 | Zymeworks Reports Positive Topline Results in Clinical Trial for Biliary Tract Cancer T.. | MT |
| 2022 | Transcript : Zymeworks Inc. - Special Call | CI |
| 2022 | Zymeworks Brief: Announcing "Positive" Topline Data in the Pivotal HERIZ.. | MT |
| 2022 | Zymeworks Inc. Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Z.. | CI |
| 2022 | Zymeworks Inc.(NasdaqGS:ZYME) added to NASDAQ Composite Index | CI |
| 2022 | Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical.. | BU |
| 2022 | Zymeworks Inc - New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cance.. | AQ |
| 2022 | New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Toda.. | BU |
| 2022 | Zymeworks Inc. Announces New Clinical Data for Zanidatamab in Her2+ /Hr+ Metastatic Bre.. | CI |
| 2022 | Zymeworks to Move Stock Listing to Nasdaq | MT |
| 2022 | Zymeworks to Transfer Stock Listing to Nasdaq | BU |
| 2022 | Zymeworks to Get Upfront Payment From Jazz Pharmaceuticals as Antitrust Period for Zani.. | MT |
| 2022 | Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab Lice.. | BU |
| 2022 | Zymeworks Inc Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab .. | CI |
| 2022 | Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto.. | AQ |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conference | BU |
| 2022 | HC Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Ratin.. | MT |
| 2022 | Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Recepto.. | BU |
| 2022 | Transcript : Zymeworks Inc., Q3 2022 Earnings Call, Nov 08, 2022 | CI |
| 2022 | Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results | BU |
| 2022 | Earnings Flash (ZYME) ZYMEWORKS Posts Q3 Loss $-0.66 | MT |
| 2022 | Zymeworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep.. | CI |
| 2022 | North American Morning Briefing: Caution to -2- | DJ |
| 2022 | HC Wainwright Downgrades Zymeworks to Neutral From Buy, Lowers Price Target to $8 From .. | MT |
| 2022 | Stifel Adjusts Zymeworks' Price Target to $18 From $21, Reiterates Buy Rating | MT |
| 2022 | SVB Securities Downgrades Zymeworks to Market Perform From Outperform, Adjusts Price Ta.. | MT |
| 2022 | Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and.. | BU |
| 2022 | Transcript : Zymeworks Inc. - Special Call | CI |
| 2022 | Sector Update: Health Care Stocks Ending Near Intra-Day Lows | MT |
| 2022 | Sector Update: Health Care | MT |
| 2022 | Top Midday Gainers | MT |
| 2022 | Sector Update: Health Care Stocks Mixed Premarket Wednesday | MT |
| 2022 | Transcript : Jazz Pharmaceuticals plc, Zymeworks Inc. - Special Call | CI |
| 2022 | Jazz Pharmaceuticals, Zymeworks Enter Into Licensing Deal for HER2-targeted Bispecific .. | MT |
| 2022 | Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab | BU |
| 2022 | Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and .. | AQ |
| 2022 | Jazz Pharmaceuticals and Zymeworks Announces Exclusive License Agreement to Develop and.. | CI |
| 2022 | Zymeworks to Host Third Quarter Results Conference Call | BU |
| 2022 | Zymeworks Completes Plan to Become Delaware Corporation | BU |
| 2022 | Zymeworks Inc. has Changed its Name to Zymeworks BC Inc | CI |
| 2022 | Zymeworks : REPORT OF VOTING RESULTS - Form 8-K | PU |
| 2022 | Zymeworks Announces Results of Special Meeting | AQ |
| 2022 | Zymeworks Announces Results of Special Meeting | BU |
| 2022 | Zymeworks Reminds Shareholders to Vote FOR its Redomicile | BU |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research a.. | AQ |
| 2022 | Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research &.. | BU |
| 2022 | Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile | BU |
| 2022 | Zymeworks : Shareholder Director Nominations - Form 8-K | PU |
| 2022 | Zymeworks Says Proxy Advisory Firm Glass Lewis Recommends Approval of Redomicile Plans | MT |
| 2022 | Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR .. | BU |
| 2022 | Transcript : Zymeworks Inc. Presents at Morgan Stanley 20th Annual Global Hea.. | CI |
| 2022 | Citigroup Lowers Zymeworks Price Target to $21 From $27, Maintains Buy Rating | MT |
| 2022 | Zymeworks Presents Early-Stage Results for Prospective Cancer Therapy | MT |
| 2022 | Transcript : Zymeworks Inc. - Special Call | CI |
| 2022 | Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at.. | BU |
| 2022 | Zymeworks Inc. Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin At E.. | CI |
| 2022 | Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve .. | BU |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
